- News
- Press release
07/12/09
Very positive 3-year results of the long-term study
Category: Products, Group activities
These results provide confirmation of the clinical relevance of Oralair.
27/11/09
Stallergenes is granted a marketing authorization for Oralair in Europe
Category: Group activities, Products
Obtention of the European approval in both adults and children through a Mutual Recognition Procedure.
16/09/09
Immunotherapy tablet containing recombinant allergen of birch pollen: positive results for a phase IIb/III trial
Category: Products
First results of a new phase IIb/III clinical trial (VO59.08) conducted in allergic rhinitis caused by birch pollen.
27/08/09
A brand name for the 2nd sublingual desensitization tablet produced by Stallergenes
The tablet for allergic rhinitis caused by exposure to dust mites has been given the following brand name: “ACTAIR”
26/08/09
First half-year 2009: performance ahead of expectations
Net profit up 11%, Strong research and investment effort, Positive net financial position, Annual growth guidance maintained at 10%
15/07/09
Strong sales growth in 1st half-year: up 12%, Full-year guidance maintained
2nd quarter growth remained high at 9% (organic 8%), but slowed down compared with the very strong start of the year. Sales growth over the first half-year remained strong at 12% (organic 11%).
29/04/09
House dust mites desensitization tablets: Positive results from a phase IIb/III clinical trial
Category: Products
Release of the first year outcome of the VO 57.07 clinical study on a sublingual house dust mite desensitization tablet.
24/03/09
2008 : A strong performance
Strong growth in results, Sales up 16%, Net profit up 17%
Sound financial position
Proposed increase in dividend
24/03/09
Exclusive partnership with Solvay Pharmaceuticals in Russia and the CIS
Category: Partnership
Signing of an exclusive partnership agreement for the promotion and distribution of Stallergenes diagnostic and treatment products
24/03/09
Tablets coordinated within the Stalair® program
Category: Products
The development of Stallergenes tablet-form pharmaceutical products will now be coordinated within a program dubbed “STALAIR®”.
19/01/09
Oralair® Grasses obtains a pediatric Market Authorisation in Germany
Pediatric extension of the indications for Stallergenes sublingual tablets for desensitization to grass pollens.
